argenx SE (ARGNF)
USD 525.6
(0.0%)
USD 525.6
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -216.02 Million USD | 68.13% |
| 2022 | -582 Million USD | -131.9% |
| 2021 | -314.42 Million USD | 41.75% |
| 2020 | -601.03 Million EUR | -180.68% |
| 2019 | -177.81 Million EUR | -104.34% |
| 2018 | -93.06 Million EUR | -233.69% |
| 2017 | -26.79 Million EUR | -21.19% |
| 2016 | -22.17 Million EUR | -31.88% |
| 2015 | -16.52 Million EUR | -31.62% |
| 2014 | -12.37 Million EUR | -55.72% |
| 2013 | -8.29 Million EUR | 34.93% |
| 2012 | -12.56 Million EUR | -197.57% |
| 2011 | -4.22 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -150.01 Million USD | 32.15% |
| 2024 Q1 | -54.52 Million USD | -22.33% |
| 2023 Q1 | -87.15 Million USD | 13.28% |
| 2023 Q2 | -81.65 Million USD | 6.31% |
| 2023 FY | - USD | 68.13% |
| 2023 Q4 | -44.57 Million USD | 11.8% |
| 2023 Q3 | -50.53 Million USD | 38.11% |
| 2022 Q4 | -100.5 Million USD | 49.9% |
| 2022 Q2 | -169.63 Million USD | 23.56% |
| 2022 Q1 | -221.9 Million USD | -9.71% |
| 2022 Q3 | -200.63 Million USD | -18.27% |
| 2022 FY | - USD | -131.9% |
| 2021 FY | - USD | 41.75% |
| 2021 Q1 | 6.49 Million EUR | -97.85% |
| 2021 Q2 | 84.69 Million USD | 1203.2% |
| 2021 Q3 | -212.15 Million USD | -350.49% |
| 2021 Q4 | -202.26 Million USD | 4.66% |
| 2020 Q4 | 301.93 Million USD | 292.06% |
| 2020 Q3 | -157.2 Million EUR | 0.0% |
| 2020 FY | - EUR | -180.68% |
| 2019 FY | - EUR | -104.34% |
| 2019 Q1 | -17.46 Million EUR | 61.33% |
| 2019 Q2 | -47.28 Million EUR | -170.75% |
| 2019 Q3 | -35.52 Million EUR | 24.87% |
| 2019 Q4 | -72.76 Million EUR | -104.82% |
| 2018 Q4 | -45.17 Million EUR | -21.14% |
| 2018 Q2 | -11.05 Million EUR | 34.41% |
| 2018 Q1 | -16.84 Million EUR | -17.08% |
| 2018 FY | - EUR | -233.69% |
| 2018 Q3 | -37.29 Million EUR | -237.43% |
| 2017 Q1 | -8.97 Million EUR | -6.66% |
| 2017 FY | - EUR | -21.19% |
| 2017 Q4 | -14.39 Million EUR | -176.32% |
| 2017 Q3 | -5.2 Million EUR | -514.21% |
| 2017 Q2 | 1.25 Million EUR | 114.01% |
| 2016 Q4 | -8.41 Million EUR | -42.22% |
| 2016 FY | - EUR | -31.88% |
| 2016 Q3 | -5.91 Million EUR | -23.1% |
| 2016 Q2 | -4.8 Million EUR | -44.4% |
| 2016 Q1 | -3.32 Million EUR | 37.42% |
| 2015 FY | - EUR | -31.62% |
| 2015 Q4 | -5.31 Million EUR | -57.18% |
| 2015 Q3 | -3.38 Million EUR | 26.54% |
| 2015 Q2 | -4.6 Million EUR | -25.41% |
| 2015 Q1 | -3.67 Million EUR | 12.7% |
| 2014 FY | - EUR | -55.72% |
| 2014 Q4 | -4.2 Million EUR | -80.81% |
| 2014 Q2 | -3.7 Million EUR | -43.61% |
| 2014 Q1 | -2.58 Million EUR | -34.75% |
| 2014 Q3 | -2.32 Million EUR | 37.21% |
| 2013 Q3 | -30.32 Thousand EUR | 99.23% |
| 2013 Q2 | -3.93 Million EUR | -64.1% |
| 2013 Q4 | -1.91 Million EUR | -6214.01% |
| 2013 FY | - EUR | 34.93% |
| 2013 Q1 | -2.39 Million EUR | 0.0% |
| 2012 FY | - EUR | -197.57% |
| 2011 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -204.104% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -3543.555% |
| SQZ Biotechnologies Company | -64.14 Million USD | -236.794% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -1143.656% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 329.719% |
| Mesoblast Limited | -62.38 Million USD | -246.248% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -13963.552% |
| Genus plc | 73.7 Million USD | 393.111% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -3167.375% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -5990.306% |
| Marizyme, Inc. | -34.28 Million USD | -530.145% |
| ContraFect Corporation | -64.99 Million USD | -232.348% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -2362.643% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -4672.73% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -15310.316% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -8068.928% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -9196.032% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -41599.588% |
| Accustem Sciences Inc. | -3.74 Million USD | -5666.121% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -347.93% |
| EV Biologics, Inc. | -1.26 Million USD | -16948.188% |
| Q BioMed Inc. | -617.62 Thousand USD | -34876.239% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 6147.678% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -34058.918% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -9356.077% |
| Biomind Labs Inc. | -1.03 Million USD | -20780.891% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 2287.132% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -2916.545% |
| Skye Bioscience, Inc. | -13.54 Million USD | -1494.554% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -14423.417% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -863992.192% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -5461.412% |
| IMV Inc. | -35.52 Million USD | -508.115% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1261.226% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -8534.146% |
| GB Sciences, Inc. | -1.41 Million USD | -15114.123% |
| Alpha Cognition Inc. | -9.7 Million USD | -2125.757% |
| HST Global, Inc. | -5303.00 USD | -4073500.754% |
| CSL Limited | 4.78 Billion USD | 104.511% |
| Halberd Corporation | -74.27 Thousand USD | -290726.543% |
| Enzolytics Inc. | -2.12 Million USD | -10080.023% |
| Resverlogix Corp. | -11.74 Million USD | -1739.747% |
| Affymax, Inc. | -14.29 Million USD | -1411.179% |
| SYBLEU INC | -141.57 Thousand USD | -152489.9% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -6952.626% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -290.363% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 17850.456% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -14312.048% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 57121.636% |
| AVAX Technologies, Inc. | -6.11 Million USD | -3434.037% |
| Zenith Capital Corp. | -8.6 Million USD | -2410.145% |
| Genscript Biotech Corporation | -248.71 Million USD | 13.146% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1239915.2% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -8730.022% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -122623.382% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -445.005% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -7368.835% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -20546.141% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 3212816.359% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -12244.181% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -11145.864% |
| BioStem Technologies, Inc. | -7.55 Million USD | -2759.852% |
| ONE Bio Corp. | 13.61 Million USD | 1686.883% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -119191.752% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -10401.85% |
| Agentix Corp. | -1.37 Million USD | -15647.921% |
| LadRx Corporation | 412.28 Thousand USD | 52496.788% |
| Cell Source, Inc. | -4.27 Million USD | -4956.097% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -58726.442% |
| Regen BioPharma, Inc. | 1.46 Million USD | 14835.984% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -22956.009% |
| NovAccess Global Inc. | -1.03 Million USD | -20775.887% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 2539.89% |
| Itoco Inc. | -1.86 Million USD | -11458.246% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -56805.076% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -19256.904% |
| Kadimastem Ltd | -2.62 Million USD | -8131.39% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -90229.52% |
| CytoDyn Inc. | -18.02 Million USD | -1098.198% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -273246.554% |
| Mobile Lads Corp. | -2.24 Million USD | -9538.899% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -1766381.707% |
| Qrons Inc. | -40.08 Thousand USD | -538866.213% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -44378.656% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 41057.439% |
| Rebus Holdings, Inc. | -951 Thousand USD | -22615.357% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -20240.962% |
| International Stem Cell Corporation | 202 Thousand USD | 107042.103% |
| Bioxytran, Inc. | -3.82 Million USD | -5554.836% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -410278.131% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -8674.533% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -502.256% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -479951.218% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -7789.812% |
| Neutra Corp. | -181.24 Thousand USD | -119087.103% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -971.596% |
| PureTech Health plc | -11.62 Million USD | -1757.943% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -971.67% |
| IXICO plc | -707 Thousand USD | -30454.887% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -2710.97% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -346.827% |
| CSL Limited | 4.73 Billion USD | 104.564% |
| Cellectis S.A. | -92.63 Million USD | -133.196% |